Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience Inc. (VIGL) is a pioneering biotechnology company developing novel therapies that target microglia dysfunction in neurodegenerative diseases. This dedicated news hub provides investors and researchers with timely updates on clinical trials, scientific advancements, and strategic developments.
Access comprehensive coverage of VIGL's progress in Alzheimer's research, rare neurological disorders, and innovative treatment approaches. Our curated collection includes earnings reports, regulatory milestones, partnership announcements, and analysis of therapeutic pipeline developments.
Key updates feature progress on the company's TREM2 agonist programs, monoclonal antibody therapies, and biomarker validation studies. Stay informed about clinical trial phases, research collaborations, and scientific presentations through verified press releases and objective reporting.
Bookmark this page for streamlined access to essential VIGL updates. Combine our news monitoring with SEC filings and investor resources for complete due diligence on this microglia-focused biotech innovator.
Vigil Neuroscience (NASDAQ: VIGL) presented data on VG-3927, its oral small molecule TREM2 agonist, at the AD/PD™ 2025 International Conference. The company shared results from both preclinical studies and Phase 1 SAD/MAD trial for potential Alzheimer's disease treatment.
Key findings from the Phase 1 trial involving 115 participants showed:
- Favorable safety and tolerability profile with no serious adverse events
- High CNS penetrance with CSF to unbound plasma ratio of 0.91
- Maximum sTREM2 reduction of approximately 50% at 25mg dose
- Support for once-daily dosing at 25mg for Phase 2 trial
Preclinical data demonstrated VG-3927's ability to enhance microglial uptake of both Aβ and Tau in 5xFAD plaque-burdened mice, suggesting potential broader efficacy in targeting multiple AD pathologies. The company plans to advance to Phase 2 development in Q3 2025.
Vigil Neuroscience (VIGL) reported its Q4 and full year 2024 financial results, highlighting significant progress in its TREM2 programs. The company announced positive Phase 1 data for VG-3927, their oral small molecule TREM2 agonist for Alzheimer's Disease, demonstrating favorable safety and up to 50% reduction in sTREM2 in cerebral spinal fluid. A Phase 2 trial is planned for Q3 2025.
The company's financial position shows cash reserves of $97.8 million as of December 31, 2024, expected to fund operations into 2026. R&D expenses increased to $62.3 million for 2024 (from $60.9M in 2023), while G&A expenses decreased to $27.4 million (from $27.9M). Net loss for 2024 was $84.3 million.
The company expects to report final analysis from the IGNITE Phase 2 trial of iluzanebart for ALSP in Q2 2025, pursuing an accelerated approval pathway.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Stifel 2025 Virtual CNS Forum.
The company's management will engage in a fireside chat scheduled for Wednesday, March 19, 2025, at 9:00 a.m. ET. The presentation will be accessible through a live webcast, with registration available online. Additionally, the webcast will be hosted in the 'Investors' section under 'Events & Presentations' on the company's website, remaining available for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on microglia-based treatments for neurodegenerative diseases, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference. The company's management will engage in a fireside chat on February 6, 2025, at 10:30 a.m. ET.
The event will be accessible through a live webcast, for which registration is required. The presentation will also be available on the company's website in the Investors section under Events & Presentations, with the archived version remaining accessible for approximately 90 days after the event.
Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial of VG-3927, an oral treatment for Alzheimer's disease (AD). The trial, involving 115 participants across 14 cohorts, demonstrated favorable safety and tolerability profiles with no serious adverse events.
Key findings include: highly brain penetrant properties, dose-dependent reduction of sTREM2 up to 50% in cerebral spinal fluid, and consistent pharmacokinetics across different genetic variants. The company selected a 25mg once-daily oral dose for its planned Phase 2 trial, scheduled to begin in Q3 2025.
VG-3927, as the first Phase 2-ready oral TREM2 agonist, functions as both an agonist and positive allosteric modulator. The drug is designed to enhance protective microglial responses to aggregated amyloid and tau without increasing inflammation, potentially offering advantages over antibody-based treatments by avoiding ARIA risks.
Vigil Neuroscience (NASDAQ: VIGL) highlighted its 2024 achievements and 2025 milestones. The company reported significant progress in its two TREM2 agonist programs and secured a $40 million strategic investment from Sanofi. Key developments include completing enrollment of 20 patients for the IGNITE Phase 2 trial of iluzanebart and surpassing 50 participants in the ILLUMINATE natural history study for ALSP.
The FDA indicated openness to considering accelerated approval for iluzanebart in ALSP. The company's VG-3927 program showed positive interim Phase 1 data in healthy volunteers and initiated dosing in Alzheimer's disease patients. The FDA removed a partial clinical hold on the VG-3927 trial.
Looking ahead to 2025, Vigil plans to report Phase 1 data for VG-3927 in Q1 and final analysis from the IGNITE Phase 2 trial for iluzanebart in Q2.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in two major investor conferences. The company will present at the Stifel 2024 Healthcare Conference on November 18th at 4:45 p.m. ET and the Jefferies London Healthcare Conference on November 20th at 8:30 a.m. GMT. Both presentations will be in a fireside chat format. The webcasts will be accessible through the company's website's Investors section and will remain available for approximately 90 days after the presentations.
Vigil Neuroscience (NASDAQ: VIGL) reported Q3 2024 financial results with a net loss of $19.3 million, compared to $20.5 million in Q3 2023. The company ended Q3 with $111.3 million in cash and equivalents, expecting to fund operations into 2026. R&D expenses decreased to $13.8 million from $15.4 million year-over-year, while G&A expenses remained stable at $6.9 million.
Key developments include planned final analysis of the IGNITE Phase 2 trial for iluzanebart in ALSP in H1 2025, and Phase 1 clinical data for VG-3927 in Alzheimer's Disease expected in Q1 2025. The company also reported new ALSP prevalence estimates of approximately 19,000 cases in the U.S. and 29,000 in EU/UK combined.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology company focused on developing microglia-based treatments for neurodegenerative diseases, has announced its participation in the Guggenheim Healthcare Innovation Conference. The company's management will engage in a fireside chat on November 11, 2024, at 10:30 a.m. ET. A live webcast will be available for registration and can be accessed through the company's website under the Investors section. The recorded session will remain accessible for approximately 90 days after the event.
Vigil Neuroscience (Nasdaq: VIGL) announced that the FDA has removed the partial clinical hold on its Phase 1 trial of VG-3927, a potential treatment for Alzheimer's disease. The decision was based on non-clinical and clinical data from the ongoing trial. Interim data from July 2024 showed a favorable safety and tolerability profile, predictable pharmacokinetics supporting once-daily dosing, and proof of target engagement. The company has initiated dosing in Alzheimer's patients, including those with TREM2 variants. Vigil plans to report complete Phase 1 data, including results from the AD patient cohort, in Q1 2025.
